Pfizer Strikes Landmark Deal with Trump Administration to Cut Drug Prices for U.S. Patients
Pfizer Inc. has reached a sweeping agreement with the Trump Administration that will reduce prescription drug costs for U.S. patients
Read morePfizer Inc. has reached a sweeping agreement with the Trump Administration that will reduce prescription drug costs for U.S. patients
Read moreThe definitive merger agreement, valued at up to $3.5 billion, grants Roche control of the late-stage FGF21 analog, pegozafermin, for
Read moreCantargia AB has announced a landmark agreement with Japanese pharma giant Otsuka Pharmaceutical Co., Ltd., granting Otsuka exclusive global rights
Read moreSanofi has announced a definitive agreement to acquire Blueprint Medicines, a U.S.-based biopharmaceutical company focused on systemic mastocytosis (SM) and
Read moreSanofi has announced a definitive agreement to acquire clinical-stage biotech firm Vigil Neuroscience, Inc., in a move to expand its
Read moreBioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire clinical-stage biotech Inozyme Pharma, Inc. for approximately $270 million
Read moreIn a strategic move to expand its oncology pipeline, GSK plc (LSE/NYSE: GSK) announced on Tuesday, it has entered into
Read moreMerck KGaA is moving forward with the acquisition of SpringWorks Therapeutics, confirming a definitive agreement at $47 per share in
Read moreLexicon Pharmaceuticals announced an exclusive worldwide licensing agreement with Novo Nordisk for LX9851, a first-in-class oral non-incretin therapy in development for
Read moreIn a significant move to expand its oncology portfolio, Taiho Pharmaceutical Co., Ltd. has entered a definitive agreement to fully
Read more